JAHA:代谢组学在心血管疾病风险预测上的运用

2017-09-29 MedSci MedSci原创

代谢组学是一种新兴的发现心血管生物标志物的有力工具。近日,在国际心血管权威杂志JAHA上发表了一篇旨在综合评估代谢组学与心血管疾病发生关系的荟萃分析。本研究搜索了截至2016年1月MEDLINE和EMBASE数据库的相关文献,纳入标准是:人类的临床研究;运用了不可知论或者综合性的方法;采用血清或者血浆作为生物样本;在研究前瞻性疾病的背景下进行基线代谢物分析;心血管事件包括卒中、心梗或者心源性死亡。

代谢组学是一种新兴的发现心血管生物标志物的有力工具。近日,在国际心血管权威杂志JAHA上发表了一篇旨在综合评估代谢组学与心血管疾病发生关系的荟萃分析。本研究搜索了截至2016年1月MEDLINE和EMBASE数据库的相关文献,纳入标准是:人类的临床研究;运用了不可知论或者综合性的方法;采用血清或者血浆作为生物样本;在研究前瞻性疾病的背景下进行基线代谢物分析;心血管事件包括卒中、心梗或者心源性死亡。最终,共纳入分析了12个原始临床研究(包括9个队列和3个巢氏病例对照研究),质谱分析法是主要的研究方法,代谢产物多样性的异质性很高,从31到>10000。与心血管疾病风险相关联的代谢物有:酰基肉碱、多种氨基酸和脂肪酸。通过这些代谢物,可以提高传统的心血管疾病风险预测效果。本荟萃分析结果显示,目前研究代谢组学与心血管疾病风险的临床研究数量有限,虽然有些代谢产物可以提高预测效果,但仍需更全面标准化的临床研究进一步证实。原始出处:Miguel R et al.Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1267556, encodeId=8229126e55658, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473075, encodeId=2f8314e3075cf, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480280, encodeId=637914802802f, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485941, encodeId=49a3148594190, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498291, encodeId=e02814982910a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Oct 01 00:52:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248769, encodeId=c98e248e691b, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Sep 29 11:12:08 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 flysky120

    学习一下知识了

    0

相关资讯

JACC:2型糖尿病患者的心超分型

2型糖尿病(T2DM)能影响患者的心脏结构和功能,但是高血压、肥胖或者高龄同样可以引起相似的改变。近日,在国际心血管权威杂志JACC上发表了一篇旨在通过聚类分析将T2DM患者的心脏表型与临床预后联系在一起的临床研究。本研究纳入了842例T2DM患者,并对其基础的超声心动图特点和复合终点事件(心源性死亡率和住院率)进行评估。最终,共将患者分成了3个聚类。第一类患者拥有最低的左室质量分数和二尖瓣早期流

JACC:抑制蛋白磷酸酶-1活性可以改善心衰患者的左室、左房收缩功能

心衰患者的蛋白磷酸酶-1水平的升高引起的一系列分子水平的变化对心肌细胞是有害的,既往动物模型研究显示通过过表达I-1c抑制蛋白磷酸酶-1的活性可以逆转心肌细胞的功能损伤。本研究通过引起猪的二尖瓣重度反流造成容量负荷型心衰模型,造模成功1个月后,将猪随机分成冠脉注射BNP116.I-1c(n=6)组或生理盐水组(n=7),随后,对其有效性和安全性随访评估2个月。此外,24只幼猪分别接受了不同剂量的B

Heart:冠心病危险因素的管理存在性别差异

近日,在国际心血管权威杂志《Heart》上发表了一篇旨在评估性别差异对冠心病(CHD)患者危险因素管理影响的临床研究。本研究纳入了2012年至2013年来自欧洲、亚洲和中东地区的冠心病患者,对其接受的指南指导下的治疗管理和生活方式进行全面的评估并比较其差异。最终共纳入10112名冠心病患者,女性占29%。与男性患者相比,女性患者更难控制其总胆固醇水平(OR 0.50, 95% CI 0.43 -

JCEM:接受性激素疗法对变性人心血管健康的影响如何?

尽管对心血管健康存在有限的作用,跨性别者(俗称,变性人)接受交叉性激素治疗以产生所需的第二性征。但这种治疗方案对他们的心血管结局有着怎样的具体影响?来自美国的研究人员进行了一项系统回顾和荟萃分析。

Hepatology:一项20年的社区研究:NAFLD发病率趋势及对代谢并发症、死亡率的影响

NAFLD发病率增加了5倍,尤其是在成年青少年患者中。NAFLD是疾病的结果,也是代谢并发症的先驱因素。代谢并发症削弱了NAFLD对死亡率的影响,免除了对心血管事件的影响。

JACC:家族性高胆固醇血症的临床标准诊断 vs 基因检测

对非选择性的低密度脂蛋白胆固醇(LDL-C)升高的患者中进行遗传筛查来确诊家族性高胆固醇血症(FH)的意义并不大。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估基因检测确诊为FH伴有急性冠脉综合征患者的发病率,并对比临床诊断FH和基因检测FH的诊断价值。本研究纳入了103例年龄≤65岁,LDL-C水平≥160mg/dl并伴有急性冠脉综合征的患者,对其7个FH易感基因(LDLR, APOB,